Culture transformation Financial Updates
lapOran Tahunan | annual report
2013
pT Indofarma persero Tbk
48
Analisis Ekonomi Makro Industri
analYSIS Of InduSTrY and MaCrOeCOnOMIC
tiga isu besar ekonomi global yang mengguncang perekonomian indonesia di tahun 2013. Mulai dari
ketidakpastian mengenai percepatan pemulihan global, ketidaktegasan kebijakan pemerintah Amerika Serikat terkait
penarikan stimulus kebijakan moneter hingga ketidakpastian perkembangan harga komoditas. Situasi ini membuat
pemerintah indonesia dan bank indonesia mengoreksi kebijakan ekonomi yang telah ditetapkan di awal. Langkah
yang telah ditempuh antara lain dengan menaikkan suku bunga bi rate dan melakukan stabilisasi nilai tukar rupiah.
Walaupun telah menempuh berbagai langkah koreksi di atas, pertumbuhan ekonomi tahun 2013 tidak mencapai target awal
APBN-P 2013 dari 6,3 menjadi 5,7. Akan tetapi, kondisi ini masih terbilang lebih tinggi bila dibandingkan dengan negara-
negara tetangga lainnya dengan perkiraan rata-rata sekitar 3,6.
Bila dilihat dari Produk Domestik Bruto PDB Indonesia hingga triwulan iii tahun 2013 tumbuh sebesar 5,83 bila dibandingkan
dengan periode yang sama di tahun 2012. Dari segi ekspor
three major issues of global economic economies rocked indonesia in 2013. Starting from the uncertainty about the
acceleration of global recovery, the United States government policy indecisiveness related to the withdrawal on stimulus
of monetary policy to the uncertainty of commodity prices. this situation makes the government of indonesia along
with bank indonesia to review the initial economic policies. the measurements that have been taken among others are
to increase the bi rate and to stabilize the exchange rate of rupiah.
Despite all the eforts, the 2013 economic condition is still far from the initial estimation of the 2013 APBN-P; shifted from
6.3 to 5.7. even so, this condition is higher when compared
with other peer countries with an estimated average of about 3.6.
In terms of national Gross Domestic Product GDP, until the third quarter of 2013, the gDp grew by 5.83 when compared to the
same period in 2012. from the exports side, the Ministry of trade
Maintaining the Stability of Competitiveness in a Challenging year
barang, Kemendag memperhitungkan bahwa indonesia memang mengalami penurunan sekitar 3 hingga 4.
beralih ke daya beli, DbS group research menyatakan bahwa keputusan pemerintah indonesia untuk meningkatkan harga
bbM bersubsidi di tengah tahun mempengaruhi daya beli masyarakat. padahal daya beli sangat erat kaitannya dengan
konsumsi masyarakat yang merupakan salah satu indikator fundamental perekonomian satu negara. pernyataan ini juga
diperkuat dengan data yang telah dikumpulkan oleh badan Pusat Statistik BPS bahwa nilai Indeks Tendensi Konsumen
ITK di triwulan pertama tahun 2013 diprediksi sebesar 107,80. nilai itK ini lebih rendah ketimbang kondisi di itK di triwulan iv
2012 yang tercatat sebesar 108,63. Dari sisi sumber daya, banyak perusahaan di indonesia juga
terkena imbas yang cukup besar terhadap kenaikan Upah Minimum Provinsi UMP yang terjadi hampir bersamaan
dengan kenaikan bbM. Secara umum, rangkaian peristiwa ini menyebabkan turunnya kinerja perusahaan di indonesia.
assumed that Indonesia has sufered a decline of about 3 to 4.
turning to purchasing power, DbS group research states that the indonesian government’s decision to raise the price of
subsidized fuel in the middle of the year has greatly afected the people’s purchasing power; though purchasing power is
closely associated with the national consumption which is the biggest fundamental to indonesia’s economy. this statement
is also supported by data collected by the Central Statistics Agency BPS that the Consumer Tendency Index ITK in the
irst quarter of 2013 is predicted at 107.80. The value is lower than the conditions in Q4 in 2012 which was recorded at
108.63. When looking from the resources perspective, many
companies in Indonesia are also afected by the increase in provincial minimum wage UMP that occurred almost
simultaneously with the rise of fuel prices. the series of unfortunate events have afected the performance of
indonesian companies into unfavorable conditions.
lapOran Tahunan 2013 | annual report
49 Total Pasar
Pasar Panel IDA
IHP IPA
Pasar Non-Panel Etikal klinik, dokter, dll
Obat BebasOTC super market, warung
total Market panel Market
IDA ihp
IPA non-panel Market
Ethical clinic, doctor, etc OTC supermarket, kiosk
52.009 21.694
5.787 7.301
8.607 30.315
13.834 16.481
45.761 19.568
5.146 6.107
8.315 26.193
12.364 13.830
13,7 10,9
12.5 19,6
3,5 15,7
11,9 19,2
100,0 41,7
11,1 14,0
16,5 58,3
26,6 31.7
DESKRIPSI PASAR MARKET DESCRIPTION
Kuartal III – 2013 Kuartal III – 2012
Pertumbuhan Pangsa Pasar
Quartal III - 2013 Quartal III - 2012
Growth Market Share
Dalam jutaan rupiah In million Rupiahs
Sumber: data dari IMS health ITMa Q3 2013 Source: from the data of IMS health ITMa Q3 2013
tabel Pasar farmasi nasional 2013
table of 2013 national pharmacy Market
lapOran Tahunan | annual report
2013
pT Indofarma persero Tbk
50
berlanjut ke pasar industri farmasi, di tahun 2013, industri farmasi mengalami pertumbuhan sebesar 13,7 dimana
pasar OTC tumbuh lebih baik 16,2 dibanding pasar ethical 11,9. Untuk pasar ethical, penyebaran produk di panel
market lebih tinggi dibandingkan non-panel market sehingga
diperkirakan pasar tender dan reguler mulai menurun. Untuk pasar otC, penyebaran produk di non-panel market lebih tinggi
sehubungan dengan karakter produk yang pada umumnya bersifat komoditi tersedia di outlet-outlet terkecil seperti mini
market, warung dan lain-lain. pertumbuhan otC yang cukup baik didominasi oleh
pertumbuhan produk-produk yang berasal dari food suplement. hal ini membuktikan bahwa pasar otC memiliki potensi
yang cukup baik untuk dikembangkan sehubungan dengan meningkatnya tingkat pendidikan di masyarakat. Kondisi ini
merubah pola pembelian masyarakat yang mengarah kepada “self medication” untuk penyakit tertentu yang dapat dihilangkan
dengan mengobati gejalanya. tren akan tindakan preventif dalam menjaga kesehatan semakin marak di masyarakat yang
menyebabkan produk-produk suplemen kesehatan dan health food makin diminati.
pangsa pasar farmasi masih didominasi oleh perusahaan domestik sebesar 73,32 sedangkan perusahaan asing memiliki
pangsa pasar 26,67. pangsa pasar tertinggi didominasi oleh produk-produk otC dan lokal ethical branded
65,53. Sedangkan pangsa pasar obat generik total sebesar 8.
Diperkirakan pangsa pasar obat generik akan meningkat di tahun 2014 sehubungan dengan diberlakukannya bpJS di awal
tahun 2014 yang sebagian besar kebutuhannya adalah obat generik. perusahaan asing pun melirik pasar generik walaupun
saat ini pangsa pasarnya baru sekitar 0,21. Sedangkan pertumbuhan pasar obat generik meningkat setiap
tahunnya di atas pertumbuhan pasar total farmasi Rp4,2 triliun; pertumbuhan 17,02. Di tahun 2013 pangsa pasar obat generik
mencapai sebesar 8 dari total pasar farmasi. going to the market condition in the pharmaceutical industry, in
2013, the pharmaceutical industry grew by 13.7 in which the OTC market grew better 16.2 compared to the ethical market
11.9. For ethical market, product deployment in the panel market is higher than the non-panel market which arguably
makes the tender and regular market began to decline. for the otC market, the spread of non-panel products is higher in
respect to the character of the product which can be described as commodity that is generally available in outlets such as the
smallest mini-markets, shops and others. the growth in otC is dominated by products that come from
food supplement. this proves that the otC market has good potential to be developed which in accordance to the increasing
level of information dissemination in the community. this condition alter the purchasing patterns that lead people to
“self-medication” for a particular disease that can be eliminated by treating the symptoms. trends on preventive measures
in maintaining health is increasingly prevalent in society that causes health products as well as food supplements have
become attractive. the pharmaceutical market share is still dominated by domestic
companies as much as 73.32, while foreign companies 26.67. the highest market share is owned by otC and local ethical
branded 65.53. While the total generic market share is 8. it is expected that the market share of generic products will
increase in 2014 along with the enforcement of bpJS in early 2014 where the requirement is mostly generic products. foreign
companies have also started to glance at the generic market despite the current market share is only about 0.21.
As for the generic market, it constantly experiences an increase annually over the total pharmaceutical market growth
Rp4, 2 trillion; rose 17.02. In 2013, the market share of generic products reach 8 of the total pharmaceutical market.
Maintaining the Stability of Competitiveness in a Challenging year lapOran Tahunan | annual report
2013 51
Analisis Kinerja Operasional
OperaTIOnal perfOrManCe analYSIS
Produksi
Dalam rangka resertiikasi CPOB fasilitas produksi yang ada, indofarma melakukan renovasi terhadap beberapa fasilitas
produksi yang mencakup penyempurnaan sistem HVAC Gedung Produksi Utama GPU, dan perbaikan fasilitas produksi
Cephalosporin injeksi Kering serta renovasi fasilitas produksi
herbal. Semua kegiatan renovasi tersebut adalah dalam rangka perbaikan fasilitas produksi namun tidak secara langsung
meningkatkan kapasitas produksi. Kegiatan renovasi untuk fasilitas gpU dilaksanakan pada semester i tahun 2013.
Adanya kegiatan renovasi tentunya berdampak terhadap pelaksanaan proses produksi. Untuk menjamin
keberlangsungan pasokan produksi maka Manajemen perusahaan mengoptimalkan pelaksanaan toll Manufacturing.
toll Manufacturing menyumbang 29 dari total produksi indofarma di tahun 2013.
indofarma juga meremajakan mesin-mesin yang sudah tidak sesuai dengan teknologi terkini melalui pengadaan beberapa
mesin baru berupa mesin cetak tablet dan penyalutan tablet. Peremajaan mesin diharapkan dapat meningkatkan eisiensi
dan efektivitas proses produksi.
output produksi pada tahun 2013 meningkat secara nilai 11 dibandingkan tahun lalu. output produksi yang dihasilkan meliputi
sediaan-sediaan padat non-betalaktam, padat betalaktam, cair, semi padat, steril non-cephalosporin, steril cephalosporin, dan
herbal.
Production
Due to the recertiication of c-GMP certiicate, the existing production facilities are being renovated which include
the perfection the HVAC system of Primary Production Building GPU and improvement of production facilities of
Dry Cephalosporin injection. in addition, the Company also
renovated the herbal production facility. the entire renovation processes above were done in order to improve the production
facilities, however does not directly increase the production capacity. the renovation of gpU facility was carried out in the
irst half while the other facilities were done in the second half. The renovation activities certainly afected the production
process. to ensure the supply availability, the management implemented the toll Manufacturing Company. toll
Manufacturing contributes 29 of the total production in 2013.
indofarma also rejuvenates old machineries through the provision of new machineries for printing and coating tablets.
It is expected that the eiciency level of production process will also increase.
production output in 2013 increased 11 in value compared to last year. the output includes the solid dosage of non-
betalactam and betalactam, liquid dosage, semi-solid dosage, non-cephalosporin sterile dosage, cephalosporin sterile dosage,
and herbal medicine.
lapOran Tahunan | annual report
2013
pT Indofarma persero Tbk
52
tablet non betalaktam Kapsul non betalaktam
tablet betalaktam Sirup Kering betalaktam
Sirup Cair botol Sirup Kering non betalaktam
Sirup Kering Cephalosporine Salep
Serbuk injeksi Cair
injeksi Kering tetes Mata
Kapsul herbal non betalactam tablet
non betalactam Capsule betalactam tablet
Dry Syrup betalactam Liquid Syrup Bottle
Dry Syrup non betalactam Dry Syrup Cephalosporine
ointment powder
Liquid Injection Dry injection
eye Drops herbs Capsule
butir butir
butir botol
botol botol
botol tube
Sachet Ampul
vial botol
butir piece
piece piece
bottle bottle
bottle bottle
tube Sachet
Ampoule vial
bottle piece
1.970.299.251 253.126.990
156.840.910 2.086.618
13.397.923 579.958
630.060 13.501.947
18.613.680 26.666.210
1.527.538 776.100
9.640.054 2.013.286.839
248.978.690 170.243.000
811.262 39.253.497
348.644 813.889
21.264.190 37.114.940
44.273.749 999.635
821.880 10.098.775
2,18 1,64
8,55 61,12
192,98 39,88
29,18 57,49
99,40 66,03
34,56 5,90
4,76
BentuK sediaan satuan
2012 2013
PertuMBuhan
Unit Dosage Form
2012 2013
Growth
tabel realisasi Produksi 2013
table of production realization of 2013
Pemasaran dan Distribusi
MarKeTIng and dISTrIbuTIOn
Sales Contribution of indofarma and non-indofarma product
Kontribusi penjualan produk indofarma dan non-indofarma
Sales Contribution regular and tender Market
Kontribusi penjualan pasar reguler dan tender
product portfolio of indofarma 2013
portofolio produk indofarma 2013
tender regular
ogb branded generic
over the Counter Diagnostic
export indofarma
non-indofarma 54
46
2 5
52 48
89 2
2
Maintaining the Stability of Competitiveness in a Challenging year lapOran Tahunan | annual report
2013 53
Sales Contribution by Distributor of indofarma product
Kontribusi penjualan Distributor produk indofarma
Sales Contribution through outlet
Kontribusi penjualan melalui outlet
igM Apotek
pharmacy
pedagang besar farmasi pharmaceutical Wholesalers
others rumah Sakit
hospital
Lain-lain others
Dinas Kesehatan KabKodya health DistrictMunicipality
Analisis Kinerja Keuangan
fInanCIal perfOrManCe analYSIS
Kinerja laba rugi Komprehensif indofarma per 31 desember 2013